GSK is reportedly in talks to acquire cancer drugmaker Nuvalent for more than $9 billion. The potential deal would be a meaningful strategic expansion in oncology for GSK and a sizable premium-scale biotech transaction. While still unconfirmed, the reported negotiations could move both names and signal continued consolidation in healthcare and biotech.
GSK is reportedly in talks to acquire cancer drugmaker Nuvalent for more than $9 billion. The potential deal would be a meaningful strategic expansion in oncology for GSK and a sizable premium-scale biotech transaction. While still unconfirmed, the reported negotiations could move both names and signal continued consolidation in healthcare and biotech.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.45
Ticker Sentiment
